Efficacy of Semi-rigid Ureteroscopic Laser Lithotripsy in the Treatment of Proximal Ureteral Stones: a Randomized Controlled Trial
Launched by ZHONGNAN HOSPITAL · Jun 28, 2024
Trial Information
Current as of August 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to study a treatment method for patients with proximal ureteral stones, which are small stones located in the upper part of the urinary tract. The researchers want to compare the effectiveness of two types of lasers used in a procedure called semi-rigid ureteroscopic laser lithotripsy. This is a technique where a small telescope is used to reach the stones and break them up using laser energy, making them easier to pass out of the body.
To participate in this trial, individuals need to be at least 18 years old and diagnosed with a single stone in the proximal ureter that is 2 cm or smaller, confirmed by imaging tests. They also need to be willing to take part in the study. However, some people may not be eligible, including those who have certain medical conditions or complications, such as an untreated urinary infection or specific anatomical issues. If someone decides to participate, they will receive the laser treatment as part of the trial and be monitored for its effectiveness in breaking up their stones.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. ≥18 years old;
- • 2. patients diagnosed with unilateral proximal ureteral stones ≤2cm by computed tomography (CT)/Kidney and upper bladder (KUB) radiography who required surgery;
- • 3. patients who volunteered to participate in this study.
- Exclusion Criteria:
- • 1. Unable to give informed consent;
- • 2. Untreated urinary tract infection;
- • 3. Pregnant women;
- • 4. Known anatomical abnormalities (such as urinary diversion or ureteral stenosis);
- • 5. Urothelial tumors, transplanted kidney stones, irreversible coagulopathy;
- • 6. The semi-rigid ureteroscope cannot reach the stone site, ureteroscopy-negative stones, and stones can be removed directly without laser lithotripsy;
- • 7. The researchers believe that they are not suitable for participation in this study.
About Zhongnan Hospital
Zhongnan Hospital, affiliated with Wuhan University, is a leading medical institution in China renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on multidisciplinary collaboration, the hospital employs state-of-the-art facilities and a team of highly skilled professionals to conduct rigorous clinical studies aimed at improving patient outcomes. Zhongnan Hospital prioritizes ethical standards and patient safety, ensuring adherence to regulatory requirements while fostering a culture of scientific excellence. As a prominent sponsor of clinical trials, the hospital plays a pivotal role in contributing to the global medical community and enhancing the understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported